Illimis Therapeutics secures $42m in Series B funding to advance its GAIA-based Alzheimer’s therapeutics. Existing investors and new supporters participated in the round. The company plans to explore immune disorders and expand its drug portfolio. The GAIA platform focuses on TAM receptor biology to target inflammation and immune responses.

CEO Sanghoon Park aims to conquer diseases with high unmet clinical needs through TAM biology understanding. DSC Investment sees Illimis’ technology as a next-gen treatment for neuro-immune diseases. The company collaborated with Lilly to advance neurodegenerative disease applications. Illimis focuses on innovative drug development and global leadership in TAM biology.

The partnership with Lilly Catalyze360-ExploR&D focuses on advancing the platform for neurodegenerative disease applications. Illimis aims to provide treatment options worldwide through R&D collaboration models. The company’s goal is to offer innovative solutions for patients in need.

Read more at Yahoo Finance: Illimis secures funding for GAIA-based Alzheimer’s therapeutics